Skip to main content

Table 2 Factors associated with failure to complete 12 weeks on study

From: Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

   Did not complete week 12 Completed week 12 p-value
N   7 23  
CTx Median (IQR) 656 (492, 811) 141 (88, 229) 0.002
BSAP Median (IQR) 44 (26, 68) 15 (14, 22) 0.005
TGF-β, ng/ml Median (IQR) 26.3 (16.8, 30.7) 20.7 (17.1, 25.5) 0.38
Activin-A, pg/ml Median (IQR) 2922 (1666, 9576) 517 (404, 775) <0.001
NTx Median (IQR) NA 158 (73, 282) -
P1NP Median (IQR) 123075 (80014, 178930) 54334 (36692, 77623) 0.002
BSP Median (IQR) 63.9 (55.3, 90.4) 15.9 (8.2, 32.9) 0.004
FACT-BP Median (IQR) 15 (7, 36) 12 (5, 23) 0.37
BPI Median (IQR) 57 (12, 65) 6 (0, 29) 0.049
# of SRE, pre , study (n = 25) 0 1 10  
1 0 9  
2 1 4  
# of SRE , on or post, study (n = 25) 0 2 16  
1 0 3  
2 0 3  
3 0 1  
Duration of bone mets, in months Median (IQR) 28 (18, 41) 18 (12, 29) 0.19
Time from primary to bone mets (n = 25) <2 years 1 12  
2–5 years 0 5  
  >5 years 1 6